Breast density is a crucial factor in mammography and breast cancer detection. Recent updates by the FDA have brought about significant changes in how breast density is reported and understood. Here’s what you need to know about these updates and how they impact you.
Understanding Breast Density
Breast density refers to the proportion of fibrous and glandular tissue compared to fatty tissue in the breasts, as seen on a mammogram. It is categorized into four levels:
- Almost entirely fatty
- Scattered areas of fibroglandular density
- Heterogeneously dense – May obscure small masses
- Extremely dense – Lowers the sensitivity of mammography
Dense breast tissue can make it more challenging to detect cancer using mammography and is also associated with an increased risk of breast cancer.
New Federal Reporting Requirements
As of September 2024, mammogram reports must include specific language regarding breast density. Patients will receive a summary indicating whether their breast tissue is dense or not dense. This is crucial for understanding personal breast cancer risk and determining the need for additional screening.
Supplemental Screening Options
Radiology Regional recommends Abbreviated Breast MRI (AB-MRI) for supplemental screening, especially for those at higher risk. However, insurance coverage may vary, and self-pay options are available.
For those with dense breast tissue, supplemental screening can be beneficial. Options include:
- Abbreviated Breast MRI: Detects 9-15 additional cancers per 1,000 patients, offering high sensitivity and specificity.
Making Informed Decisions
Talk with your healthcare provider to help tailor your breast cancer screening plan. Together you can consider your risk factors and the potential benefits of supplemental screening to make informed decisions about your health.
For more information on supplemental screening visit: Abbreviated Breast MRI – Radiology Regional
